Defence Therapeutics (TSE:DTC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Defence Therapeutics Inc.’s innovative ARM-X anti-cancer vaccine has demonstrated significant success in combating pre-established ovarian cancer in animal studies, achieving complete responses when used with an anti-PD-1 immune-checkpoint inhibitor. This advancement in Defence’s Accum® platform marks the fourth cancer model successfully targeted by their ARM-X vaccine, offering a promising outlook for future oncology treatments.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.